Previous close | 11.15 |
Open | 10.85 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 9.30 - 11.15 |
Contract range | N/A |
Volume | |
Open interest | N/A |
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript May 8, 2024 Teva Pharmaceutical Industries Limited misses on earnings expectations. Reported EPS is $-0.12161 EPS, expectations were $0.51. Teva Pharmaceutical Industries Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
Stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Wednesday's market close with the Dow Jones Industrial Average holding in the green. After topping fiscal third-quarter revenue estimates and narrowing expected losses per share, Affirm shares (AFRM) are now sinking in the afternoon and analysts have an idea of what the cause is. Tripadvisor (TRIP), Teva Pharmaceutical Industries (TEVA), and Dutch Bros (BROS) are also reporting earnings. Defiance ETFs CEO and CIO Sylvia Jablonski joins Market Domination for the latest installment of Yahoo Finance's Good Buy or Goodbye to talk about the latest trend in clean energy investing: Uranium. Dine Brands (DIN) CEO John Peyton — whose company owns IHOP and Applebee's — discusses consumer spending patterns at his restaurants. This post was written by Luke Carberry Mogan.